Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
The Affiliated Hospital of Qingdao University
Modality
Cell therapy
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06544720CT.gov SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Penile Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| scg142 tcr-t cells (this asset) | The Affiliated Hospital of Qingdao University | P1 | CC · 43 |
| Cyclophosphamide | Christian Hinrichs | P2 | BB |
| Fludarabine | Christian Hinrichs | P2 | BB |
| e7 tcr-t cells | Christian Hinrichs | P2 | B |
| Cabozantinib | National Cancer Institute (NCI) | P2 | B |
| 9-valent human papillomavirus recombinant vaccine | Shanghai Bovax Biotechnology Co., Ltd. | P3 | B |
| Nivolumab | National Cancer Institute (NCI) | P2 | B |
| Ipilimumab | National Cancer Institute (NCI) | P2 | B |
| Alpha-Interferon | Hoag Memorial Hospital Presbyterian | P2 | B |
+20 more in the Penile Cancer cohort
Other indications for scg142 tcr-t cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Human Papillomavirus-Related Squamous Cell Carcinoma | — | P1 | CC · 43 |
| Head And Neck Cancer | — | P1 | CC · 43 |
| Vulva Cancer | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. scg142 tcr-t cells in Penile Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/scg142-tcr-t-cells-penile-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →